A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

NCT05650203 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped the research and develop strategy of Product JS009 adjustment

Conditions

Primary Condition: Advanced Tumors

Interventions

DRUG: JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006

Sponsor

Shanghai Junshi Bioscience Co., Ltd.